10-K: SINTX Technologies 2025 10-K: Strategic Shift to Biomedical, Revenue Declines

Sentiment:

Annual Report 20 March 2026 5:00 PM

📋All filings for Sintx Technologies, INC

SINTX Technologies reports a significant revenue decline in 2025 due to a strategic shift away from low-margin OEM contracts towards proprietary silicon nitride biomedical devices, while securing FDA clearance for a new foot and ankle system.

Capital raiseEntered into an At The Market (ATM) Offering Agreement in October 2025 to sell shares of common stock with an aggregate offering price of $6.4 million, with $6.0 million remaining capacity as of December 31, 2025.Entered into a warrant inducement agreement in September 2025, leading to the exercise of existing warrants for approximately $3.8 million in gross proceeds and the issuance of new common stock purchase warrants.Closed a private placement in February 2025 for aggregate gross proceeds of $5.0 million, issuing common stock, pre-funded warrants, and common warrants.Closed public offerings in February, March, and April 2024, raising approximately $4.0 million, $1.3 million, and $1.5 million respectively.The company explicitly states it will require substantial future capital and continues to seek opportunities to raise additional funding through equity and/or debt financing.

Worse than expectedTotal revenue decreased by 65% in 2025 compared to 2024.Product revenue decreased by 41% and grant and contract revenue decreased by 82%.Gross profit decreased by 78%.The company continues to incur significant net losses ($10.364 million in 2025) and negative operating cash flows ($8.6 million).Substantial doubt exists about the company's ability to continue as a going concern.

Summary

SINTX Technologies is an advanced ceramics company focused on silicon nitride biomaterials for medical, industrial, and agribiotech applications.
The company reported a total revenue of $1.018 million in 2025, a 65% decrease from $2.887 million in 2024.
Net loss for 2025 was $10.364 million, a slight improvement from $11.024 million in 2024.
Cash used in operations remained consistent at $8.6 million for both 2025 and 2024.
The company received FDA 510(k) clearance for its SiNAPTIC Foot & Ankle Osteotomy Wedge System in October 2025, marking its commercial entry into reconstructive foot and ankle surgery.
A strategic repositioning is underway, moving away from non-core, low-margin OEM technical manufacturing contracts to focus on proprietary silicon nitride-based biomedical devices.
The company sold its TA&T subsidiary in February 2025 and ceased efforts to make the armor plant operational in August 2024, incurring a $4.6 million impairment charge in 2024.
SINTX acquired Sinaptic Surgical, LLC assets in July 2025, issuing warrants to purchase 325,000 shares of common stock and receiving $750,000 in cash.
An At The Market (ATM) Offering Agreement was entered into in October 2025 to sell up to $6.4 million in common stock, with $6.0 million remaining capacity as of December 31, 2025.
A warrant inducement agreement in September 2025 led to the exercise of existing warrants for $3.8 million and the issuance of new warrants valued at $6.7 million, treated as a deemed dividend.
The company has an accumulated deficit of $292.1 million as of December 31, 2025, and substantial doubt exists about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for SINTX, marked by significant revenue decline and ongoing losses, despite strategic shifts and product clearances. The going concern doubt and need for substantial future capital indicate high financial risk.

Positives

FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System in October 2025 enables commercial entry into reconstructive foot and ankle surgery in the U.S.
Received issuance of International Patent No. 7635292 and U.S. Patent No. 11,591,217 for novel agricultural uses of silicon nitride, particularly in plant protection and antimicrobial treatment.
Granted U.S. patent application titled "Antipathogenic Fibrous Materials" and received a Notice of Allowance for a patent application covering antipathogenic fabric technology in 2025.
Strategic repositioning to focus on higher-margin proprietary silicon nitride-based biomedical devices is expected to drive sustainable growth.
Acquisition of Sinaptic Surgical, LLC assets in July 2025 expands the biomedical product portfolio.
Sublease agreement for the SINTX armor facility in October 2025 is expected to save approximately $1.0 million over the sublease term.
Net loss decreased slightly from $11.024 million in 2024 to $10.364 million in 2025.
Strong intellectual property portfolio with twenty-one issued U.S. patents and ten issued foreign patents, with the latest expiring in 2042.
Sole provider of silicon nitride medical devices and the only FDA-registered and ISO 13485:2016 certified silicon nitride medical device manufacturing facility globally.
Developing AI-designed 3D printing capabilities for Custom and Patient-Specific medical implants using SiN/PEEK formulation.

Negatives

Total revenue decreased by 65% from $2.887 million in 2024 to $1.018 million in 2025, primarily due to strategic repositioning away from low-margin OEM contracts.
Product revenue decreased by 41% ($0.5 million) and grant and contract revenue decreased by 82% ($1.4 million) in 2025 compared to 2024.
Gross profit decreased by 78% ($1.6 million) in 2025 compared to 2024.
Incurred a net loss of $10.364 million in 2025 and $11.024 million in 2024.
Used $8.6 million in cash from operations in both 2025 and 2024.
Accumulated deficit of $292.1 million as of December 31, 2025.
Substantial doubt exists about the company's ability to continue as a going concern for 12 months from the date of financial statement issuance.
Requires substantial future capital to continue operations, research, development, and commercialization efforts.
Raising additional capital will likely cause dilution to existing stockholders or involve restrictive debt covenants.
Limited market acceptance of silicon nitride-based products to date.
Highly competitive orthopedic market dominated by larger companies with greater resources.
Reliance on a limited number of third-party suppliers for key raw materials without supply agreements.
Building and managing an in-house sales and distribution organization subjects the company to significant operational, financial, and execution risks.
The safety and effectiveness of products are not supported by long-term clinical data.
A deemed dividend related to warrant inducement of $6.719 million was recognized in 2025.

Risks

Will require additional financing, and failure to obtain funding would force delays, reductions, or elimination of product development or commercialization efforts.
Raising additional capital by issuing securities or through debt financings or licensing arrangements may dilute existing stockholders, restrict operations, or require relinquishing proprietary rights.
Incurred net losses since inception and may never achieve or sustain profitability.
Success depends on the ability to successfully commercialize advanced ceramic products for biomedical and antipathogenic applications, which have experienced only limited market acceptance.
May not be able to compete effectively against larger, well-established companies or emerging innovative companies.
Dependence on aerospace and biomedical customers' ability to sell manufactured products.
Inability to manufacture advanced ceramic products on a timely basis consistent with quality standards would adversely impact results.
Dependence on a limited number of third-party suppliers for key raw materials; loss or inability to supply could harm the business.
Establishing and developing OEM partnerships and arrangements subjects the company to various risks, including lower profitability and compliance costs.
If hospitals and other healthcare providers cannot obtain coverage or adequate reimbursement for procedures using products, widespread adoption is unlikely.
Prolonged negative economic conditions may adversely affect the company, suppliers, partners, and consumers.
Dependence on senior management team, engineering team, and external advisors; loss of any could harm the business.
Cybersecurity risks and failure to maintain integrity of data could expose the company to disruptions, data loss, litigation, and reputational harm.
Contracting with government entities exposes the company to additional risks and regulatory requirements.
Uncertainty in obtaining regulatory clearance or approval and commercializing biomedical or antipathogenic product candidates in a timely manner or at all.
Limited experience conducting clinical trials, which may proceed slowly, and product candidates may not be shown safe and effective.
Relationships with third-party payers and customers may be subject to various laws and regulations, exposing the company to sanctions, penalties, and reputational harm.
U.S. federal income tax reform could adversely affect the company.
Legislation may increase difficulty and cost for regulatory approval and affect product prices.
Inadequate patent, trade secret, and contractual protection for intellectual property could harm commercialization and profitability.
No patent protection covering the composition of matter for solid silicon nitride or all manufacturing process components, allowing competitors to create similar formulations.
Potential for intellectual property litigation, consuming resources and affecting business.
May be subject to damages from claims of wrongful use or disclosure of trade secrets or breach of non-competition agreements.
Conflict with intellectual property rights of others could prevent manufacturing or marketing.
Potential product liability claims or claims relating to improper handling of hazardous materials, which could be costly.
As a smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors.
May not be able to maintain listing on the Nasdaq Capital Market, adversely affecting price and liquidity.

Future Outlook

The company expects product revenue to increase in 2026, driven by the SiNAPTIC Foot & Ankle Osteotomy Wedge System and a private label agreement for OsseoSculpt. The strategic shift towards proprietary silicon nitride-based biomedical devices is anticipated to lead to sustainable growth and improved operating results over time, despite continued investment in R&D and regulatory approvals.

Management Comments

The decrease in total revenue was primarily due to the Company's ongoing strategic repositioning away from non-core, low-margin OEM technical manufacturing contracts that did not support long-term profitability.
This planned reduction in OEM-related revenue is consistent with our corporate shift toward commercializing proprietary silicon nitride-based biomedical devices, which we believe offer stronger margins, a more defensible competitive position, and better long-term value for shareholders.
While this strategic realignment has led to a decline in reported revenue, we believe it is a necessary step in positioning the Company for sustainable growth.
Our strategic emphasis is focused on utilizing our technology in making advancements in the biomedical sector.
Through this transformation, as demonstrated by the recent FDA 510(k) clearance of our SiNAPTIC Foot & Ankle Osteotomy Wedge System, our aim is to deliver meaningful innovations to the medical community.
By focusing on partnerships and collaborations with healthcare institutions and industry leaders, we believe that we are positioned to expand our footprint in the medical device sector and drive shareholder value through sustainable, high-impact innovations.

Industry Context

StockSavvy.ai notes that SINTX Technologies' strategic pivot towards high-value biomedical applications, particularly with silicon nitride, aligns with a broader industry trend of seeking advanced biomaterials for improved patient outcomes and reduced infection risks in orthopedics. The focus on AI-designed 3D printing for patient-specific implants also positions the company within the growing personalized medicine market, which demands innovative material combinations like SiN/PEEK for enhanced mechanical performance and imaging compatibility. However, the highly competitive orthopedic market, dominated by large players like Medtronic, Johnson & Johnson, Stryker, and Zimmer Biomet, presents significant challenges for market penetration and requires substantial investment in clinical data and distribution.

Comparison to Industry Standards

SINTX silicon nitride is presented as superior to PEEK, allograft/autograft bone, metal, and traditional oxide ceramics in spine implants due to properties like bone growth promotion, antibacterial/antiviral/antifungal characteristics, imaging compatibility, hardness, strength, fracture resistance, and non-corrosive nature.
In an in vivo study, the force required to separate SINTX silicon nitride from bone was approximately three times that of PEEK and nearly two times that of titanium in the absence of bacteria. In the presence of bacteria, it was over five times that of titanium, while PEEK showed virtually no osteointegration.
Live bacteria counts were 8 to 30 times lower on SINTX silicon nitride than PEEK and up to 8 times lower than titanium in an in vitro study (Acta Biomater. 2012).
SINTX silicon nitride's flexural strength is more than five times that of PEEK, and its compressive strength is over twenty times that of PEEK.
The company believes its silicon nitride joint implant product candidates could have higher wear resistance than metal-on-cross-linked polyethylene and traditional oxide ceramic-on-cross-linked polyethylene implants, which are common in total hip replacements.
SINTX claims to be the only FDA-registered and ISO 13485:2016 certified silicon nitride medical device manufacturing facility in the world, and the only provider of structural ceramics-based medical devices for spinal fusion applications.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President	NA	Ryan Elmore	2026-03-16	Appointment to lead business and operational strategy.
Chief Investment Officer	Chief Strategy Officer	Gregg Honigblum	2025-05-01	Change in role from Chief Strategy Officer.
Chief Financial Officer	Corporate Controller	Kevin Trask	2025-09-01	Promotion from Corporate Controller.
Director	Sonny Bal	NA	2025-04-01	Tenure on the Board of Directors ended.
Director	David Truetzel	NA	2025-04-01	Tenure on the Board of Directors ended.
Director	Jeffrey White	NA	2025-04-01	Tenure on the Board of Directors ended.
Director	Eric Stookey	NA	2025-04-01	Tenure on the Board of Directors ended.
Director	Mark Froimson	NA	2025-04-01	Tenure on the Board of Directors ended.
Director	NA	Jay M. Moyes	2025-04-01	Appointment to the board of directors.
Director	NA	Robert D. Mitchell	2025-04-01	Appointment to the board of directors.
Director	NA	Chris Lyons	2025-04-01	Appointment to the board of directors.
Director	NA	Mark Anderson	2025-04-01	Appointment to the board of directors.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	Board of Directors is divided into three classes with staggered three-year terms. Class I: Eric Olson, Jay Moyes (terms expire 2027). Class II: Robert Mitchell, Chris Lyons (terms expire 2028). Class III: Gregg Honigblum, Mark Anderson (terms expire 2026).	NA	Enhances likelihood of continuity and stability in board composition, potentially delaying or preventing future takeovers not approved by the board.
Director Removal	Members of the board of directors may only be removed for cause and only by the affirmative vote of holders of at least 80% of outstanding voting stock.	NA	Increases the time required for stockholders to change board composition, making it more difficult to effect a change in a majority of directors.
Blank Check Preferred Stock Authorization	Board of directors is authorized to issue, without stockholder approval, blank check preferred stock.	NA	Can operate as a defensive measure (poison pill) by diluting stock ownership of a potential hostile acquirer, preventing unapproved acquisitions.
Advance Notice Provisions for Stockholder Proposals/Nominations	Restated Bylaws require timely written notice for stockholder proposals and director nominations (90-120 days prior to annual meeting anniversary, or 60-90 days for special meeting).	NA	Discourages certain tactics used in proxy fights and makes it more difficult for stockholders to bring business or nominate directors without prior board approval.
Special Meetings of Stockholders	Special meetings of stockholders may be called only by the board of directors pursuant to a majority resolution.	NA	Limits stockholders' ability to call special meetings, centralizing control with the board.
No Stockholder Action by Written Consent	Restated Certificate of Incorporation does not permit stockholders to act by written consent, requiring actions at duly called meetings.	NA	Ensures all stockholder actions occur at formal meetings, preventing rapid changes outside of scheduled events.
Super-Majority Stockholder Vote for Certain Actions	Requires affirmative vote of at least 80% of outstanding voting stock to amend or repeal anti-takeover provisions or reduce authorized common/preferred stock.	NA	Makes it significantly harder for stockholders to alter key corporate governance provisions or capital structure without broad consensus, protecting existing anti-takeover measures.
Equity Incentive Plan	The 2025 Equity Incentive Plan was approved by shareholders on September 4, 2025, reserving 700,000 shares for awards, with an automatic annual increase starting January 1, 2026.	2025-09-04	Provides a framework for attracting and retaining talent through equity compensation, aligning employee incentives with company performance, but also allows for potential dilution.
Executive RSU Vesting Acceleration	Board of Directors approved the acceleration of vesting for all unvested RSUs granted in May 2025 to executives.	2025-11-01	Increases immediate compensation for executives, potentially boosting morale and retention, but also impacts stock-based compensation expense.
Related Party Transaction Policy	Adopted a written policy for review and approval of related party transactions, requiring Audit Committee review and approval/ratification for transactions exceeding $120,000 or 1% of average total assets.	NA	Enhances transparency and oversight of potential conflicts of interest, protecting shareholder interests.

Legal Proceedings

Currently not a party to any material legal proceedings. However, the industry is characterized by frequent claims and litigation, including intellectual property and product liability.

Related Party Transactions

Entered into a Research Collaboration Agreement with a company majority-owned by a shareholder, funding it with $500,000 in 2025.

Stakeholder Impact

Shareholders: Potential for significant dilution from future capital raises; strategic shift aims for long-term value but current financial performance is weak; anti-takeover provisions limit shareholder influence on control changes.
Employees: Workforce reduction in 2024; new executive appointments and equity incentive plan aim to attract and retain talent; cybersecurity risks could impact employee data.
Customers: Focus on high-quality silicon nitride products for biomedical applications aims to improve patient outcomes; dependence on customer sales and reimbursement policies.
Suppliers: Dependence on a limited number of third-party suppliers creates supply chain risk.
Creditors: Going concern doubt raises concerns about the company's ability to meet future obligations.

Next Steps

Commercialization of the SiNAPTIC Foot & Ankle Osteotomy Wedge System in the United States, with revenue expected to begin in the first half of 2026.
Commercialization of OsseoSculpt through a private label agreement, with revenue recognition beginning in the second half of 2025.
Continued investment in the development and regulatory advancement of silicon nitride-based orthopedic and surgical implants.
Development of new silicon nitride manufacturing technologies, including porous and textured implants and new composite products.
Application of silicon nitride technology platform to new medical opportunities (foot and ankle, dental, maxillofacial, arthroplasty) and seeking OEM/private label partnerships.
Development of new products with antipathogenic properties, including inactivation of SARS-CoV-2, with several partnerships exploring opportunities in face masks, filters, wound care, and coatings.
Continued efforts to raise additional funding through equity and/or debt financing.
Evaluation of the impact of ASU 2024-03 on consolidated financial statements, with adoption effective for annual periods beginning after December 15, 2026.
Automatic annual increase in shares available under the 2025 Equity Incentive Plan starting January 1, 2026.

Key Dates

Date	Description
1996-12-01	SINTX Technologies formed.
2008-01-01	SINTX silicon nitride products first implanted in humans.
2018-09-05	Asset Purchase Agreement with CTL Medical for spine implant business.
2020-01-01	Discovery that SINTX silicon nitride inactivates SARS-CoV-2.
2021-07-01	Acquisition of armor equipment (SINTX Armor facility).
2023-10-01	SINTX Armor facility completely shut down due to malfunctioning sintering furnace.
2024-02-02	Closed public offering of 80,000 units (Common Units and Pre-Funded Warrant Units) for $4.0 million gross proceeds.
2024-03-26	Closed public offering of 142,000 common shares for $1.3 million gross proceeds.
2024-04-05	Closed public offering of 358,000 common shares for $1.5 million gross proceeds.
2024-05-28	Effected a 1-for-200 reverse stock split.
2024-08-08	Board approved a company-wide reduction in workforce.
2024-08-12	Board approved plan to cease efforts to make the armor plant operational.
2024-08-01	Eric Olson appointed Chief Executive Officer.
2024-11-01	Eric Olson appointed to the board of directors.
2024-11-01	Gregg Honigblum served as Chief Strategy Officer.
2025-02-19	Entered into Entity Acquisition Agreement with Tethon Corporation to sell TA&T subsidiary.
2025-02-20	Entered into Securities Purchase Agreement for $5.0 million gross proceeds, issuing common stock, pre-funded warrants, and common warrants.
2025-03-27	Registration Statement on Form S-3 for resale of securities declared effective by SEC.
2025-04-01	Jay M. Moyes, Robert D. Mitchell, Chris Lyons, and Mark Anderson appointed to the board of directors.
2025-05-02	Eric Olson and Gregg Honigblum granted 55,000 restricted stock units each.
2025-05-05	Entered into new Executive Employment Agreements with Eric Olson and Gregg Honigblum.
2025-05-01	Gregg Honigblum served as Chief Investment Officer.
2025-07-01	Entered into Asset Purchase Agreement with Sinaptic Surgical, LLC to acquire assets.
2025-09-04	Shareholders approved the 2025 Equity Incentive Plan.
2025-09-08	Entered into warrant inducement agreement with certain warrant holders.
2025-09-01	Kevin Trask appointed Chief Financial Officer.
2025-10-01	Received FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System.
2025-10-03	Entered into At The Market Offering Agreement for $6.4 million in common stock.
2025-10-01	Sublease agreement for SINTX armor facility entered into.
2025-11-01	Sublease term for SINTX armor facility commenced.
2025-11-01	Board of Directors approved acceleration of vesting for unvested RSUs granted in May 2025 to executives.
2026-02-02	FDA's Quality Management System Regulation (QMSR) becomes effective.
2026-03-13	Number of shares outstanding of common stock was 4,121,727.
2026-03-16	Ryan Elmore appointed President of SINTX Technologies, Inc.
2026-03-20	Date of filing of the Annual Report on Form 10-K.
2026-01-01	Number of shares available under the 2025 Plan will automatically increase by the lesser of (i) 10% of the Company's outstanding shares or (ii) such lesser number as determined by the Board.
2028-10-01	Remaining term of exclusive broker agreement with CTL Medical for manufacturing services.
2031-10-01	Expiration of lease for 30,764 sq ft corporate office and manufacturing facilities.
2031-10-31	Expiration of sublease for SINTX armor facility.
2042-01-01	Latest expiration date for SINTX's issued patents.

Recommendation

hold

SINTX Technologies is undergoing a significant strategic transformation, pivoting from lower-margin OEM work to higher-value proprietary biomedical devices. While the FDA clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System and strong intellectual property in advanced ceramics are positive developments, the company faces substantial financial challenges, including a sharp revenue decline, ongoing net losses, and a "going concern" warning. The need for significant future capital raises and the highly competitive market add considerable risk. A "hold" recommendation is appropriate for investors who are already exposed to the stock and believe in the long-term potential of the strategic shift and the underlying silicon nitride technology, but acknowledge the high execution risk and current financial weakness. New investors should exercise extreme caution given the going concern risk and consider waiting for clearer signs of financial stabilization and successful market penetration of new products.

Keywords

Silicon Nitride, Biomaterials, Medical Devices, Orthopedics, Spinal Implants, Foot & Ankle Surgery, FDA Clearance, Advanced Ceramics, Antipathogenic, Intellectual Property, Nasdaq, 10-K, Financial Reporting, Corporate Governance, Risk Factors, Capital Raise, Manufacturing, Healthcare, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.